-+ 0.00%
-+ 0.00%
-+ 0.00%

CytoSorbents Expects Q4 Revenue To Be ~$9.2M And FY25 Revenue Of ~$37M, With Expected Q4 Gross Margins In Range Of 73%-75%

Benzinga·01/12/2026 12:25:04
Listen to the news

Fourth quarter and Full-Year 2025 revenue are expected to be approximately $9.2 million and $37.0 million, respectively, with expected Q4 gross margins in the range of 73% to 75%

DrugSorb®-ATR De Novo Pre-Submission Meeting scheduled with the FDA this month, with anticipated De Novo Application filing this quarter and regulatory decision in mid-2026

Results of the pivotal STAR-T study for DrugSorb®-ATR have recently been accepted for publication in a top cardiac surgery journal

Management will host in-person investor meetings in San Francisco during J.P. Morgan Healthcare Conference week

PRINCETON, N.J., Jan. 12, 2026 /PRNewswire/ -- CytoSorbents Corporation (NASDAQ:CTSO), a leader in the treatment of life-threatening conditions in the intensive care unit and cardiac surgery using blood purification, today announced preliminary unaudited fourth quarter and full-year 2025 financial results and business update.

Preliminary, Unaudited Selected Fourth Quarter and Full-Year Financial Results

  • Fourth quarter 2025 revenue is expected to be approximately $9.2 million compared to $9.2 million in the fourth quarter of 2024
  • Full-year 2025 revenue is expected to be approximately $37.0 million, representing approximately 4% growth versus $35.6 million for the full-year 2024
  • Fourth quarter gross margin is expected to be in the range of 73% to 75%, compared to 71% in the fourth quarter of 2024, and 70% in the third quarter of 2025
  • Full-year gross margin is expected to be approximately 72%, compared to 71% for full-year 2024